ZA200403406B - [[2-(Amino-3,4-dioxo-icyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain - Google Patents

[[2-(Amino-3,4-dioxo-icyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain Download PDF

Info

Publication number: ZA200403406B
Authority: ZA; South Africa
Prior art keywords: pain; dioxo; amino; acid; day
Prior art date: 2001-10-10

Application number

ZA200403406A

Other languages

English (en)

Inventor

Brandt Michael Richard

Moyer John Allen

Zaleska Margaret Maria

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-10

Filing date

2004-05-05

Publication date

2007-04-25

2004-05-05 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-04-25 Publication of ZA200403406B publication Critical patent/ZA200403406B/en

Links

208000002193 Pain Diseases 0.000 title claims description 74
230000036407 pain Effects 0.000 title claims description 68
238000011282 treatment Methods 0.000 title claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 25
239000002253 acid Substances 0.000 claims description 22
125000000217 alkyl group Chemical group 0.000 claims description 18
229910052739 hydrogen Inorganic materials 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 16
-1 5-tetraazolyl Chemical group 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 15
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
150000002431 hydrogen Chemical group 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
238000000034 method Methods 0.000 claims description 7
208000004296 neuralgia Diseases 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
208000000094 Chronic Pain Diseases 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 5
125000002947 alkylene group Chemical group 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
208000021722 neuropathic pain Diseases 0.000 claims description 5
208000004454 Hyperalgesia Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
206010058019 Cancer Pain Diseases 0.000 claims description 3
102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 claims description 3
101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 claims description 3
208000027418 Wounds and injury Diseases 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
239000001961 anticonvulsive agent Substances 0.000 claims description 3
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
206010019233 Headaches Diseases 0.000 claims description 2
208000035154 Hyperesthesia Diseases 0.000 claims description 2
208000004983 Phantom Limb Diseases 0.000 claims description 2
125000004450 alkenylene group Chemical group 0.000 claims description 2
230000003556 anti-epileptic effect Effects 0.000 claims description 2
229960003965 antiepileptics Drugs 0.000 claims description 2
101150047356 dec-1 gene Proteins 0.000 claims description 2
231100000869 headache Toxicity 0.000 claims description 2
208000015181 infectious disease Diseases 0.000 claims description 2
125000005394 methallyl group Chemical group 0.000 claims description 2
239000003053 toxin Substances 0.000 claims description 2
231100000765 toxin Toxicity 0.000 claims description 2
108700012359 toxins Proteins 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims 3
230000002981 neuropathic effect Effects 0.000 claims 3
229940116254 phosphonic acid Drugs 0.000 claims 3
208000008035 Back Pain Diseases 0.000 claims 2
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 2
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 2
239000000014 opioid analgesic Substances 0.000 claims 2
208000033808 peripheral neuropathy Diseases 0.000 claims 2
HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 claims 1
101100162200 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflD gene Proteins 0.000 claims 1
208000018380 Chemical injury Diseases 0.000 claims 1
IVHVNMLJNASKHW-UHFFFAOYSA-M Chlorphonium chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CC1=CC=C(Cl)C=C1Cl IVHVNMLJNASKHW-UHFFFAOYSA-M 0.000 claims 1
208000001640 Fibromyalgia Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
206010028836 Neck pain Diseases 0.000 claims 1
206010056238 Phantom pain Diseases 0.000 claims 1
206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
230000001154 acute effect Effects 0.000 claims 1
208000007502 anemia Diseases 0.000 claims 1
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
230000001363 autoimmune Effects 0.000 claims 1
230000001580 bacterial effect Effects 0.000 claims 1
229940000635 beta-alanine Drugs 0.000 claims 1
150000001721 carbon Chemical group 0.000 claims 1
229940000425 combination drug Drugs 0.000 claims 1
230000007812 deficiency Effects 0.000 claims 1
LZPBLUATTGKZBH-UHFFFAOYSA-L fenoprofen calcium Chemical compound O.O.[Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 LZPBLUATTGKZBH-UHFFFAOYSA-L 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
239000003112 inhibitor Substances 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
210000005036 nerve Anatomy 0.000 claims 1
201000001119 neuropathy Diseases 0.000 claims 1
230000007823 neuropathy Effects 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
125000005499 phosphonyl group Chemical group 0.000 claims 1
239000004576 sand Substances 0.000 claims 1
230000000697 serotonin reuptake Effects 0.000 claims 1
238000001356 surgical procedure Methods 0.000 claims 1
230000000542 thalamic effect Effects 0.000 claims 1
230000003612 virological effect Effects 0.000 claims 1
230000009278 visceral effect Effects 0.000 claims 1
208000009935 visceral pain Diseases 0.000 claims 1
230000000694 effects Effects 0.000 description 14
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 11
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 10
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 8
108091006146 Channels Proteins 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 6
230000002411 adverse Effects 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
229960003299 ketamine Drugs 0.000 description 6
241000700159 Rattus Species 0.000 description 5
150000001931 cyclobutenes Chemical class 0.000 description 5
230000002385 psychotomimetic effect Effects 0.000 description 5
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 4
229960001985 dextromethorphan Drugs 0.000 description 4
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 4
229960004640 memantine Drugs 0.000 description 4
229940127523 NMDA Receptor Antagonists Drugs 0.000 description 3
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 3
229920000768 polyamine Polymers 0.000 description 3
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
102000034570 NR1 subfamily Human genes 0.000 description 2
108020001305 NR1 subfamily Proteins 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
208000004550 Postoperative Pain Diseases 0.000 description 2
206010039897 Sedation Diseases 0.000 description 2
LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 description 2
206010053552 allodynia Diseases 0.000 description 2
229960003805 amantadine Drugs 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
229950004794 dizocilpine Drugs 0.000 description 2
208000002173 dizziness Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229960003998 ifenprodil Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
125000003884 phenylalkyl group Chemical group 0.000 description 2
XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000036280 sedation Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
210000003934 vacuole Anatomy 0.000 description 2
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MPTBIGGYGATXPP-UHFFFAOYSA-N 6-(2h-tetrazol-5-ylmethyl)-2,6-diazabicyclo[5.2.0]non-1(7)-ene-8,9-dione Chemical compound C1=2C(=O)C(=O)C=2NCCCN1CC1=NN=NN1 MPTBIGGYGATXPP-UHFFFAOYSA-N 0.000 description 1
241001006782 Amage Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
101100338765 Danio rerio hamp2 gene Proteins 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
229940122459 Glutamate antagonist Drugs 0.000 description 1
102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
101150043052 Hamp gene Proteins 0.000 description 1
101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
101100079886 Lactobacillus johnsonii (strain CNCM I-12250 / La1 / NCC 533) nfr2 gene Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
108020002076 NR2 subfamily Proteins 0.000 description 1
102000038100 NR2 subfamily Human genes 0.000 description 1
108091008644 NR2D Proteins 0.000 description 1
240000007673 Origanum vulgare Species 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 1
108010038912 Retinoid X Receptors Proteins 0.000 description 1
102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
125000004144 cyclobuten-1-yl group Chemical group [H]C1=C(*)C([H])([H])C1([H])[H] 0.000 description 1
CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
239000003257 excitatory amino acid Substances 0.000 description 1
230000002461 excitatory amino acid Effects 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
230000004907 flux Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
239000003825 glutamate receptor antagonist Substances 0.000 description 1
108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
229960001410 hydromorphone Drugs 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-O hydron piperazine Chemical compound [H+].C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-O 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
230000007659 motor function Effects 0.000 description 1
DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
210000001002 parasympathetic nervous system Anatomy 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229950009825 selfotel Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000003956 synaptic plasticity Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960004394 topiramate Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA200403406A 2001-10-10 2004-05-05 [[2-(Amino-3,4-dioxo-icyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain ZA200403406B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32824501P	2001-10-10	2001-10-10

Publications (1)

Publication Number	Publication Date
ZA200403406B true ZA200403406B (en)	2007-04-25

Family

ID=23280159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200403406A ZA200403406B (en)	2001-10-10	2004-05-05	[[2-(Amino-3,4-dioxo-icyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain

Country Status (27)

Country	Link
US (2)	US7098200B2 (de)
EP (1)	EP1434588B1 (de)
JP (1)	JP4350512B2 (de)
KR (1)	KR100922703B1 (de)
CN (1)	CN100448449C (de)
AR (1)	AR036764A1 (de)
AT (1)	ATE515266T1 (de)
AU (1)	AU2009201746A1 (de)
BR (1)	BR0213237A (de)
CA (1)	CA2461348C (de)
CY (1)	CY1111909T1 (de)
DK (1)	DK1434588T3 (de)
EA (1)	EA009993B1 (de)
ES (1)	ES2367356T3 (de)
HK (1)	HK1064609A1 (de)
HU (1)	HUP0401773A3 (de)
IL (2)	IL161275A0 (de)
MX (1)	MXPA04003354A (de)
NO (1)	NO20041378L (de)
NZ (1)	NZ532159A (de)
PL (1)	PL368863A1 (de)
PT (1)	PT1434588E (de)
SI (1)	SI1434588T1 (de)
TW (1)	TWI321472B (de)
UA (1)	UA78529C2 (de)
WO (1)	WO2003031416A2 (de)
ZA (1)	ZA200403406B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3241550T3 (da)	2002-11-22	2020-08-24	Gruenenthal Gmbh	Anvendelse af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol til behandling af inflammatoriske smerter
JP2006522834A (ja) *	2003-04-09	2006-10-05	ワイス	［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の鼻腔内投与用医薬組成物およびその使用法
PL1611144T3 (pl) *	2003-04-09	2011-03-31	Wyeth Llc	Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
US20050142192A1 (en) *	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
TW200514775A (en)	2003-10-22	2005-05-01	Wyeth Corp	Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
BRPI0516549A (pt) *	2004-10-08	2008-09-09	Wyeth Corp	derivados de ácido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil ]fosfÈnico e métodos para sua fabricação
EP2195031A1 (de) *	2007-08-27	2010-06-16	Wyeth a Corporation of the State of Delaware	Zusammensetzungen und verfahren unter einsatz von nmda-antagonisten zur herbeiführung einer eine anästhesie überflüssig machenden wirkung
AU2010213580A1 (en)	2009-02-13	2011-09-08	Allergan, Inc.	Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
MX2011009716A (es)	2009-03-19	2011-10-17	Wyeth Llc	Metodos para la preparacion de acido [2-(8,9-dioxo)-2,6-diazabicic lo[5.2.0]non-1(7)-en-2-il)etil]fosfonico y precursores de este.
EP2782569A1 (de)	2011-11-21	2014-10-01	Allergan, Inc.	Pharmazeutische zusammensetzungen mit 4-[1-(2,3-dimethylphenyl-)ethyl-]3h-imidazolderivaten zur behandlung von netzhauterkrankungen
US10292989B2 (en)	2014-03-28	2019-05-21	University Of Virginia Patent Foundation	General anesthetics that are not neurotoxic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5168103A (en) *	1991-01-22	1992-12-01	American Home Products Corporation	[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) *	1991-10-11	1992-06-23	American Home Products Corporation	Benzimidazole phosphono-amino acids
DK124393D0 (da)	1993-11-03	1993-11-03	Lundbeck & Co As H	Compounds
AT400440B (de) *	1993-12-06	1995-12-27	Vianova Kunstharz Ag	Verfahren zur herstellung von wasserverdünnbaren lackbindemitteln und deren verwendung
TW427904B (en) *	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
UA52698C2 (uk) *	1996-10-04	2003-01-15	Х. Луннбек А/С	Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
IL163574A (en)	1997-08-01	2008-06-05	Wyeth Corp	Process for the preparation of D. ester of N - [3 - (Butylcoscarbonylamino tart) - profile] - 2 - Aminoethyl phosphonic acid
US5990307A (en) *	1997-08-01	1999-11-23	American Home Products Corporation	Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
US6362371B1 (en)	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
US6225343B1 (en) *	1999-06-16	2001-05-01	Nastech Pharmaceutical Company, Inc.	Compositions and methods comprising morphine gluconate
US20030158254A1 (en)	2002-01-24	2003-08-21	Xenoport, Inc.	Engineering absorption of therapeutic compounds via colonic transporters
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain

2002
- 2002-09-10 UA UA20040503402A patent/UA78529C2/uk unknown
- 2002-10-08 AR ARP020103791A patent/AR036764A1/es unknown
- 2002-10-09 MX MXPA04003354A patent/MXPA04003354A/es active IP Right Grant
- 2002-10-09 IL IL16127502A patent/IL161275A0/xx unknown
- 2002-10-09 CA CA2461348A patent/CA2461348C/en not_active Expired - Fee Related
- 2002-10-09 PT PT02789180T patent/PT1434588E/pt unknown
- 2002-10-09 BR BR0213237-0A patent/BR0213237A/pt not_active Application Discontinuation
- 2002-10-09 TW TW091123270A patent/TWI321472B/zh not_active IP Right Cessation
- 2002-10-09 SI SI200230959T patent/SI1434588T1/sl unknown
- 2002-10-09 PL PL02368863A patent/PL368863A1/xx not_active IP Right Cessation
- 2002-10-09 DK DK02789180.3T patent/DK1434588T3/da active
- 2002-10-09 AT AT02789180T patent/ATE515266T1/de active
- 2002-10-09 JP JP2003534400A patent/JP4350512B2/ja not_active Expired - Fee Related
- 2002-10-09 KR KR1020047005298A patent/KR100922703B1/ko not_active IP Right Cessation
- 2002-10-09 CN CNB028202430A patent/CN100448449C/zh not_active Expired - Fee Related
- 2002-10-09 HU HU0401773A patent/HUP0401773A3/hu unknown
- 2002-10-09 US US10/267,159 patent/US7098200B2/en not_active Expired - Fee Related
- 2002-10-09 EP EP02789180A patent/EP1434588B1/de not_active Expired - Lifetime
- 2002-10-09 NZ NZ532159A patent/NZ532159A/en not_active IP Right Cessation
- 2002-10-09 WO PCT/US2002/032252 patent/WO2003031416A2/en active Application Filing
- 2002-10-09 EA EA200400523A patent/EA009993B1/ru not_active IP Right Cessation
- 2002-10-09 ES ES02789180T patent/ES2367356T3/es not_active Expired - Lifetime
2004
- 2004-04-02 NO NO20041378A patent/NO20041378L/no unknown
- 2004-04-04 IL IL161275A patent/IL161275A/en not_active IP Right Cessation
- 2004-05-05 ZA ZA200403406A patent/ZA200403406B/en unknown
- 2004-10-05 HK HK04107633.4A patent/HK1064609A1/xx not_active IP Right Cessation
2006
- 2006-05-12 US US11/433,737 patent/US7759346B2/en not_active Expired - Fee Related
2009
- 2009-05-01 AU AU2009201746A patent/AU2009201746A1/en not_active Ceased
2011
- 2011-08-02 CY CY20111100744T patent/CY1111909T1/el unknown

Also Published As

Publication number	Publication date
US7759346B2 (en)	2010-07-20
EP1434588B1 (de)	2011-07-06
IL161275A (en)	2009-09-01
JP4350512B2 (ja)	2009-10-21
EA009993B1 (ru)	2008-06-30
PT1434588E (pt)	2011-09-05
MXPA04003354A (es)	2004-09-28
PL368863A1 (en)	2005-04-04
CA2461348A1 (en)	2003-04-17
CN100448449C (zh)	2009-01-07
AR036764A1 (es)	2004-09-29
US20030114444A1 (en)	2003-06-19
HUP0401773A2 (hu)	2005-01-28
ATE515266T1 (de)	2011-07-15
DK1434588T3 (da)	2011-08-15
CY1111909T1 (el)	2015-11-04
WO2003031416A2 (en)	2003-04-17
EA200400523A1 (ru)	2004-08-26
US20060205696A1 (en)	2006-09-14
HUP0401773A3 (en)	2005-06-28
NZ532159A (en)	2006-02-24
AU2009201746A1 (en)	2009-05-28
US7098200B2 (en)	2006-08-29
HK1064609A1 (en)	2005-02-04
UA78529C2 (en)	2007-04-10
CN1568189A (zh)	2005-01-19
WO2003031416A3 (en)	2003-08-14
SI1434588T1 (sl)	2011-10-28
EP1434588A2 (de)	2004-07-07
KR20050034604A (ko)	2005-04-14
TWI321472B (en)	2010-03-11
ES2367356T3 (es)	2011-11-02
IL161275A0 (en)	2004-09-27
CA2461348C (en)	2011-02-15
KR100922703B1 (ko)	2009-10-22
JP2005508950A (ja)	2005-04-07
BR0213237A (pt)	2004-09-28
NO20041378L (no)	2004-05-28

Publication	Publication Date	Title
US20010036943A1 (en)	2001-11-01	Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
EP2134335B1 (de)	2014-04-23	Droxidopa und pharmazeutische zusammensetzung davon zur behandlung von fibromyalgie
US7759346B2 (en)	2010-07-20	[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
JP2003507421A (ja)	2003-02-25	トラマドール物質及び抗痙攣薬を含んで成る組成物
CA2169718C (en)	2002-11-12	The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases
CN110996947A (zh)	2020-04-10	N-甲基-d-天冬氨酸型谷氨酸受体拮抗剂反应性神经精神性疾病的联合治疗
CN113453683A (zh)	2021-09-28	运动障碍的治疗
JP2010526116A5 (de)	2011-06-23
CN1527711A (zh)	2004-09-08	用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物
WO2009053742A2 (en)	2009-04-30	Salts of nefopam and their use in therapy
EP1613328B1 (de)	2009-03-18	Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten
CN110996948A (zh)	2020-04-10	用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
JP2004508272A (ja)	2004-03-18	アセチルコリンエンハンサー
CZ289344B6 (cs)	2002-01-16	Léčivo umoľňující pacientovi, aby sám omezil konzumaci alkoholu
Tariot et al.	1997	Treating Alzheimer's disease: pharmacologic options now and in the near future
Harron	1992	Distinctive features of rilmenidine possibly related to its selectivity for imidazoline receptors
AU2004233582B2 (en)	2008-05-15	Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
ZA200300549B (en)	2003-08-19	Dementia remedies containing 2-aryl-8-oxidihydropurine derivatives as the active ingredient.
US20190054085A1 (en)	2019-02-21	Composition and method for treatment of depression and psychosis in humans
JP2009502828A (ja)	2009-01-29	Ｎｍｄａ受容体遮断薬と麻薬性鎮痛物質とを含む治療用組合せ
JPH0132806B2 (de)	1989-07-10